[HTML][HTML] Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
LM Koenig, DFR Boehmer, P Metzger… - Journal of Experimental …, 2020 - rupress.org
Journal of Experimental Medicine, 2020•rupress.org
An exacerbated and unbalanced immune response may account for the severity of COVID-
19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus
2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils
in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment
option to block neutrophil recruitment and activation.
19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus
2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils
in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment
option to block neutrophil recruitment and activation.
An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
rupress.org